MDBH MDB CAPITAL HOLDINGS LLC

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol

Trading Under New Ticker of “EXOZ” Expected to Begin February 12, 2025

Monrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ: IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. (“eXoZymes”) and an application for a new ticker symbol. The company expects trading under the new ticker symbol of “EXOZ” to begin on February 12, 2025, subject to final approvals.

In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly.

No action is required by existing shareholders with respect to the name and ticker symbol change. The Committee on Uniform Securities Identification Procedures (CUSIP) also confirmed the CUSIP number assigned to the Company's common stock will remain unchanged.

About Invizyne

Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology.

For more information, please visit  

Forward-Looking Statements

This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.

Media contacts:

Lasse Görlitz, VP of Communications

(858) 319-7135

 

Investor Relations Contact: 

 





EN
10/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDB CAPITAL HOLDINGS LLC

 PRESS RELEASE

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent...

PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.” As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remainin...

 PRESS RELEASE

MDB Capital Holdings Announces Transitions In Its Board of Directors

MDB Capital Holdings Announces Transitions In Its Board of Directors MDB Capital Holdings Announces Transitions In Its Board of Directors Jeb Terry, Sr. appointed to the board as Susanne Meline concludes dedicated and impactful board service Addison, Texas, Feb. 02, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading “Big Idea” companies, today announced the appointment of Jeb Terry, Sr to its Board of Directors and extended its sincere gratitude to Susanne Meline as she concluded her dedicated and i...

 PRESS RELEASE

PatentVest Releases New Report on the IP Battle Shaping the $1.8 Trill...

PatentVest Releases New Report on the IP Battle Shaping the $1.8 Trillion Space Economy New PatentVest Pulse analysis examines Elon Musk’s SpaceX, Jeff Bezos–backed Blue Origin, Rocket Lab, and China’s growing influence Dallas, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced the release of a new PatentVest Pulse report, The Patent Battlefield: How IP Portfolios Reveal the True Winners in the $1.8 Trillion Space Economy, a first-of-its-kind analysis using patent data to reveal who is positioned to win as the space sector goes mainstream. With Elon Musk’s SpaceX rumored ...

 PRESS RELEASE

MDB Capital Holdings Provides Third Quarter 2025 Update

MDB Capital Holdings Provides Third Quarter 2025 Update Management to Host Conference Call Today at 4:30 p.m. ET Addison, TX, Nov. 20, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading “Big Idea” companies, today provides an operational update for the quarter ended September 30, 2025, and subsequent developments. Third Quarter 2025 and Subsequent Operational Highlights Anticipate closing two offerings shortly: This week: $16.8 million private placement offering for Paulex Bio, a biopharma...

 PRESS RELEASE

MDB Capital Holdings to Host Third Quarter 2025 Update Conference Call...

MDB Capital Holdings to Host Third Quarter 2025 Update Conference Call on Thursday November 20, 2025, at 4:30 p.m. Eastern Time Addison, TX, Nov. 11, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Thursday November 20, 2025 at 4:30 p.m. Eastern Time to provide a business update for the third quarter 2025. A press release detailing the results will be issued prior to the call. Christopher Marlett, CEO and Co-Founder of MDB will lead ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch